Avacta Share Discussion Threads

[fieldhouse] 23/10/2024 11:09

My take,for what it’s worth!
Yes,ava6000 is dead in the water.
Now all about the delivery system and its ability to target tumours .
Going forward now using regenerative AI with the potential to recognise the best treatment options ,drugs to tumours.
Do not underestimate the power of AI !
For those that follow NVIDiA will recognise the potential which frankly ,is mind blowing.
A new era beckons

[amanitaangelicus] 23/10/2024 09:03

Raj. You.ve enjoyed your many pops at me. Luckily,I.ve been more correct than you have. Has our former leader been playing games? Yes, I suspect he has and why he went( pushed , unless I'll - diff story then). I think Avacta knows that the Doli / FAP idea works, looks very safe but the efficacy in terms of halting C is actually poor. Why do I think this? Their recent joint agreement they announced the other day - better warheads. It s essentially a symbiotic relationship. Both need each other. If,when they drop AVA6k , the share price will inevitably plummet to below 40p. I repeat, the leaving of Mr Enthusiasm,Agent Smith, remains massive red flag. That's my much unliked current thought processes. Time will sink this ,along with the alleged ' friendly' convis. Never have I heard such idiocy around the convis. They usually kill ya. Years of seeing this. Terminators.

[dudishes] 22/10/2024 15:29

PW, Agree your opinion.

More importantly, one may like to consider the share price

60% decline since Oct 23?

Another 5,930,659 shares to be washed through?

Figures

[rajraj b] 22/10/2024 15:09

Aman- give it a rest mate. Sounding a bit monotonous now. More importantly, do you think the CEO is lying about the trial results up to now as well?

[amanitaangelicus] 22/10/2024 14:41

Raj ...back again for yet another punt! He knows no bounds. Like clockwork. Funny as ...

[pwhite73] 22/10/2024 14:33

You have no understanding of the lengths companies go to in order to remain afloat. Everybody tows the line as their livelihoods depend on it. Everybody towed the line on the world beating LFT when with hindsight we all now know not a single word of it was true. Have you not read the news on the Post Office Horizon scandal.

The LFT failed because Porton Down and UKHSA which are government bodies were not part of the scam.

[rajraj b] 22/10/2024 14:11

'They have nothing of the kind it's all made up. 'How have they convinced the members of the newly appointed Scientific Board that the results are bogus and why have none of the board members called Avacta out on this? Maybe Christine has kidnapped a family member of each of the board members to keep them quiet? Desperate times deserve desperate measures, right? :))

[pwhite73] 22/10/2024 14:09

Boothy2003 - "Phase 1 trials are not focused on effectiveness (efficacy), though researchers may gather preliminary data on how well the drug works."

That's the point I'm making. The drug won't move onto Phase 2 if there are no early signs of efficacy otherwise honey to deal with a common cold would make it onto Phase 2 if safety, tolerance and dosage levels were the only criteria. The drug must prove some level of efficacy at the very earliest stage to move onto Phase 2.

must dash

[pwhite73] 22/10/2024 14:04

Rajraj b - "Plus they have scans showing shrinking tumour masses for patients on the trial,"

They have nothing of the kind its all made up. That's why they haven't subjected the drug to peer review. Its like you haven't learned a damned thing from the world beating first in-class LFT.

Serious question why do you think the former CEO has done a Lord Lucan or a Shergar depending on your age.

[boothy2003] 22/10/2024 14:04

Phase 1 clinical trials primarily test for safety and dosage. These trials are the first stage of testing in humans and involve a small number of participants, usually healthy volunteers (20-100 people). The main goals are to: 1. Assess Safety: Determine if the drug or treatment is safe for humans by monitoring side effects and adverse reactions. 2. Establish Dosage Ranges: Identify the appropriate dosage that can be used for later trials, starting with low doses and gradually increasing them. 3. Evaluate Pharmacokinetics: Understand how the body absorbs, distributes, metabolizes, and excretes the drug.Phase 1 trials are not focused on effectiveness (efficacy), though researchers may gather preliminary data on how well the drug works.

[rajraj b] 22/10/2024 13:58

You do realise they took multiple biopsy samples through the trials ( 2 week and 3 week) all showing active Dox in the biopsies and in large concentrations. Plus they have scans showing shrinking tumour masses for patients on the trial, who were given no hope. You really should read their decks on the AVCT website. That way you might be more up to date in your thinking and less confused about all this.

[bbd2] 22/10/2024 13:56

Drop the company sec an email and ask them the question direct if anyone is confused. I would also let then know about the Deutch note, and see what the reaction is.

[filthypoor] 22/10/2024 13:56

PWhite making it up as he goes along. DYOR and don't listen to Whitey.

Not currently invested, just looking for a lower entry point. Unlike Whitey I don't rubbish a share to try and gain that lower entry point.

[pwhite73] 22/10/2024 13:31

I'm not saying anything of the kind. What I'm saying is right from outset of any new drug trial efficacy has to be measured even at the pre-clinical stage. Efficacy has to be measured in animal and computer modelling.

RNS 18/02/2021 - "In animal models AVA6000 has been shown to significantly increase the amount of active drug in a tumour compared with the heart and has significant potential to improve tolerability and achieve better clinical outcomes for patients."

Even as far back as February 2021 they had informed you of efficacy in preclinical trials. They have not been able to prove it in Phase 1 trials that's why three years on from the first in-human trial in August 2021 they are still stuck at Phase 1a.

Enough from me today.

[rajraj b] 22/10/2024 13:08

So are you saying the design of the trial is faulty? You are confusing yourself now with this nonsense.

[pwhite73] 22/10/2024 12:34

"Challenges and Considerations in Taking a New Drug into Phase 1 Clinical Trials"

3. "Study design: Designing a rigorous study protocol that can accurately measure the safety and efficacy of a new drug is critical. The study must be carefully designed to minimize the risk of bias and ensure that the results are meaningful."

DB have stated at this stage the efficacy results of AVA6000 are not meaningful.

[pwhite73] 22/10/2024 12:27

FilthyPoor - You are completely wrong. The reason why Phase 1 drugs fail to make it to Phase 2 is no evidence of efficacy at an early stage although Phase 2 is the stage at which the drug is compared with other drugs on the market.

Indeed very few if any drugs fail Phase 1 due to safety issues as the drug is already tested on animals at the pre-clinical stage. What the FDA look for are early signs of efficacy. If it were just a question of safety a nice hot cup of tea would make it into Phase 2.

[repins1] 22/10/2024 11:54

Dox been around for donkeys and proven safe, so no safety issues how ever the claim of efficency of delivery may be questionable, lots of Dox studies trials out there to be found if seek

[pwhite73] 22/10/2024 10:43

For three years Avacta were playing the safety game knowing full well a warhead that had no release action would not pose a threat to patient safety at any dosage level.

However on the grounds of efficacy by default the drug would fail.

[pwhite73] 22/10/2024 10:38

Rajraj b - "What does this mean? For it to fail a Phase 1 wouldn’t it be needed to be found unsafe?"

No. To move onto Phase 2 there has to be proven safety and efficacy at Phase 1. We know for a fact there is 100% safety at Phase 1 because the Safety Committee agreed the dosages could be increased. Indeed so safe was the drug Avacta were never able to find a MTD (Maximum Tolerated Dose).

RNS 21/03/24. "Cohort 7 was the final cohort in the three-weekly study and even at this dose level (385 mg/m2), which is approximately 3.5x the equivalent standard dose of doxorubicin, dose-limiting toxicities were not observed and the Safety Data Monitoring Committee ("SMDC") has concluded that this dose level is safe. A number of patients remain on the three-weekly study at this time in several different cohorts."

[rajraj b] 22/10/2024 10:31

Yep you're right. They seem quite confused.

[coley15] 22/10/2024 10:07

Don't humour him / her.

[rajraj b] 22/10/2024 10:01

'1. Deutsch Bank pharmacology analysts have confirmed the drug has failed Phase 1a.'What does this mean? For it to fail a Phase 1 wouldn't it be needed to be found unsafe? Forget all other criteria , safety comes first,no?